register | login
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2022 Medicom Conference Planning
  • Disease Areas
  • Other Medical News
  • Podcast
  • Videos
  • Education
  • About
    • Vacancies
Home > Oncology > ESMO 2020

ESMO 2020


European Society for Medical Oncology 19-21 September 2020
  • Read the full Report (e-book)
  • Table of Contents
  • Colophon

Table of Contents



Featured articles

Letter from the Editor

Editor
Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

COVID-19 and Cancer

ESMO 2020 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom

COVID-19 and Cancer

COVID-19 and Cancer

Breast Cancer

CDK4/6 inhibition in high-risk early breast cancer

Neoadjuvant treatment in patients with high-risk early breast cancer

Prognostic value of tumour infiltrating lymphocytes in young TNBC patients

Contradicting results for chemoimmunotherapy in metastatic TNBC

Second-line sacituzumab govitecan improves survival in metastatic TNBC

Gastrointestinal Cancers

Rechallenge of RAS/BRAF wildtype CRC with avelumab plus cetuximab

Surveillance after curative treatment for CRC

Adjuvant chemotherapy less effective in elderly CRC patients

Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?

Lung Cancer

Preoperative immunotherapy in early stage NSCLC safe and feasible

No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC

Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence

Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC

First-line immune checkpoint inhibition in metastatic NSCLC

PD-L1 density, a new predictive biomarker in NSCLC

Atezolizumab/bevacizumab for non-squamous NSCLC with high PD-L1 expression

Consolidation ipilimumab and nivolumab in limited stage SCLC

Melanoma

Adjuvant immune checkpoint inhibition after complete resection

Immuno-combination therapy in metastatic melanoma

Genitourinary Cancers

Abiraterone in M1 hormone-naïve prostate cancer

New treatment option for patients with mCRPC

First-line treatment of advanced/metastatic RCC

First-line immune-combination therapies in mUC

Second- and third-line treatment options in mUC

Bladder cancer risk and early detection

Presented By
Dr Thibault De La Motte Rouge, Dr Wei Shen Tan, Dr Bas van Rhijn, Dr Francesco Soria

Gynaecological Cancers

Treatment of newly diagnosed ovarian cancer

Treatment of recurrent ovarian cancer

Palbociclib effective in ER-positive endometrial cancer

Basic Science

Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)

PD-(L)1, LAG-3, and TIM blockade

CRC disseminates using collective migration

site created by:   

© 2021 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT